Gene Bio Tech진바이오텍
086060 · KOSDAQ · ₩086060 · 진바이오텍
₩5,140▲ ₩60 (1.18%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩91B | ₩83B | ₩79B | ₩83B | ₩63B |
| Cost of sales | ₩76B | ₩69B | ₩66B | ₩72B | ₩55B |
| Gross profit | ₩14B | ₩14B | ₩14B | ₩10B | ₩7.6B |
| Operating income | ₩3.9B | ₩3.8B | ₩4B | ₩1.7B | −₩208M |
| Net income | ₩3.8B | ₩2.9B | ₩2.6B | ₩1.5B | −₩484M |
| Net income to shareholders | ₩3.8B | ₩2.9B | ₩2.6B | ₩1.5B | −₩493M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩76B | ₩72B | ₩66B | ₩64B | ₩60B |
| Current assets | ₩55B | ₩56B | ₩49B | ₩46B | ₩42B |
| Cash and equivalents | ₩9.6B | ₩10B | ₩8.8B | ₩7.4B | ₩7.4B |
| Total liabilities | ₩21B | ₩21B | ₩18B | ₩18B | ₩16B |
| Current liabilities | ₩16B | ₩18B | ₩15B | ₩16B | ₩14B |
| Borrowings | ₩15B | ₩16B | ₩12B | ₩13B | ₩10B |
| Total equity | ₩55B | ₩51B | ₩48B | ₩46B | ₩44B |
| Shareholders' equity | ₩55B | ₩51B | ₩48B | ₩46B | ₩44B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩7.6B | −₩464M | ₩7.4B | −₩3.7B | −₩2.8B |
| Capital spending | ₩3.8B | ₩1.1B | ₩530M | ₩1.2B | ₩3.1B |
| Free cash flow | ₩3.9B | −₩1.6B | ₩6.8B | −₩4.8B | −₩5.9B |
| Dividends paid | — | — | ₩0 | — | ₩258M |
Consolidated where available. Amounts in won.
Also known as: Gene Bio Tech / 진바이오텍 / 086060 / KRX:086060
Source: KRX statistical information